Considering its inhibition of STING-mediated antiviral response, PCSK9 might be a potential target for the treatment of COVID-19 (40), in addition to being a known therapeutic target for hypercholesterolemia (41). Here, PCSK9 is linked to familial hypercholesterolemia.